Evidence-Based Reviews

Substance use disorders in adolescents with psychiatric comorbidity: When to screen and how to treat

Current Psychiatry. 2015 April;14(4):36-39, 47-51

References

1. Johnston LD, Miech RA, O’Malley PM, et al. Monitoring the future, Table 2: trends in annual prevalence of use of various drugs in grades 8, 10, and 12. http://www. monitoringthefuture.org/data/14data.html#2014data-drugs. Published December 16, 2014. Accessed January 6, 2015.
2. Merikangas KR, He JP, Burnstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-- Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980-989.
3. Kandel DB, Johnson JG, Bird HR, et al. Psychiatric disorders associated with substance use among children and adolescents: findings from the Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study. J Abnorm Child Psychol. 1997;25(2):122-132.
4. Roberts RE, Roberts CR, Xing Y. Comorbidity of substance use disorders and other psychiatric disorders among adolescents: evidence from an epidemiologic survey. Drug Alcohol Depend. 2007;88(suppl 1):S4-S13.
5. Stowell R, Estroff TW. Psychiatric disorders in substance-abusing adolescent inpatients: a pilot study. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1036-1040.
6. National Institute of Alcohol Abuse and Alcoholism. Alcohol screening and brief intervention for youth: a practitioner’s guide. http://www.niaaa.nih.gov/ Publications/EducationTrainingMaterials/Pages/YouthGuide.aspx. Accessed March 11, 2015.
7. Children’s Hospital Boston. The CRAFFT screening interview. http://www.integration.samhsa.gov/clinical-practice/sbirt/CRAFFT_Screening_interview.pdf. Published 2009. Accessed March 11, 2015.
8. Levy S, Weiss R, Sherritt L, et al. An electronic screen for triaging adolescent substance use by risk levels. JAMA Pediatr. 2014;168(9):822-828.
9. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
10. Kelly JF, Myers MG. Adolescents’ participation in Alcoholics Anonymous and Narcotics Anonymous: review, implications and future directions. J Psychoactive Drugs. 2007;39(3):259-269.
11. Lifrak PD, Alterman AI, O’Brien CP, et al. Naltrexone for alcoholic adolescents. Am J Psychiatry. 1997;154(3):439-441.
12. Deas D, May MP, Randall C, et al. Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol. 2005;15(5):723-728.
13. Miranda R, Ray L, Blanchard A, et al. Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addict Biol. 2014;19(5):941-954.
14. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805-812.
15. Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013;38(3):1788-1791.
16. Hopfer CJ, Khuri E, Crowley TJ, et al. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002;23(3):231-237.
17. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. HHS Publication No. (SMA) 12-4214. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.
18. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157-1164.
19. Gowing L, Farrell MF, Ali R, et al. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014;3:CD002024.
20. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008; 300(17):2003-2011.
21. Fishman MJ, Winstanley EL, Curran E, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1669-1676.
22. Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev. 2003;22(3):295-297.
23. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence. J Subst Abuse Treat. 2008;13(6):382-388.
24. Deas D, Randall CL, Roberts JS, et al. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study. Hum Psychopharmacol. 2000;15(6):461-469.
25. Riggs PD, Mikulich-Gilbertson SK, Davies RD, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007;161(11):1026-1034.
26. Findling RL, Pagano ME, McNamara NK, et al. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial. Child Adolesc Psychiatry Ment Health. 2009;3(1):11.
27. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112(1-2):39-45.
28. Cornelius JR, Bukstein OG, Wood DS, et al. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009;34(10):905-909.
29. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37(2):171-178.
30. Donovan SJ, Susser ES, Nunes E. Divalproex sodium for use with conduct disordered adolescent marijuana users. Am J Addict. 1996;5(2):181.
31. Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry. 1997;58(1):12-15.
32. DelBello, M. Topiramate plus quetiapine cut Cannabis use in bipolar teens. Paper presented at: American Academy of Child and Adolescent Psychiatry’s Annual Meeting. November 2011; Toronto, Ontario, Canada.
33. Wilens TE, Biederman J, Adamson JJ, et al. Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study. Drug Alcohol Depend. 2008;95(3):188-198.
34. Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(12):1271-1278.
35. Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(4):420-429.
36. Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011;50(9):903-914.
37. Szobot CM, Rohde LA, Katz B, et al. A randomized crossover clinical study showing that methylphenidate- SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008;41(3):250-257.
38. Solhkhah R, Wilens TE, Daly J, et al. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol. 2005;15(5): 777-786.
39. Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010;49(6):573-582.
40. Zulauf CA, Sprich SE, Safren SA, et al. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep. 2014;16(3):436.
41. Riggs PD, Mikulich SK, Coffman LM, et al. Fluoxetine in drug-dependent delinquents with major depression: an open trial. J Child Adolesc Psychopharmacol. 1997;7(2):87-95.
42. Mohatt J, Bennett SM, Walkup JT. Treatment of separation, generalized, and social anxiety disorders in youths. Am J Psychiatry. 2014;171(7):741-748.
43. Strawn JR, Sakolsky DJ, Rynn MA. Psychopharmacologic treatment of children and adolescents with anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2012; 21(3):527-539.

Substance use disorders in adolescents with psychiatric comorbidity: When to screen and how to treat

References

Pages

Recommended Reading